Response to XXXX : a comparative study.

@entity1 @entity75 @entity2117 @entity1694 @entity1709 @entity74 @entity543
BACKGROUND: Vitiligo is the most common @entity74 of the skin and hair, resulting from selective destruction of melanocytes. @entity1709 , a @entity74 , presents as irregular, brown, macular @entity2117 . A small subset of @entity1694 @entity1 paradoxically also have @entity1709 . OBJECTIVE: To evaluate and compare the response to @entity543 in a group of @entity1 with @entity1694 , and another group of @entity1 with @entity1694 and coexisting @entity1709 ( @entity1709 ). METHODS: @entity1 in both groups were treated with @entity543 and a comparison of the zonal repigmentation was made at 4, 8, and 12 weeks after the initiation of therapy. RESULTS: At the end of 12 weeks, 86% of @entity1 in the @entity1709 group attained >= 75% pigmentation on the face, whereas this was achieved in only 12.5% of @entity1 in the @entity1694 group. Over the limbs, 73% of @entity1 in the @entity1709 group attained 75% or more pigmentation at the end of 12 weeks compared with only 9% in the @entity1694 group. On the trunk, only 20% of @entity1709 @entity1 showed >= 75% pigmentation at 12 weeks compared with 63% of @entity1 in the @entity1694 group. CONCLUSION: @entity1 having both @entity1694 and @entity1709 have a significantly better prognosis for repigmentation on the face and limbs with @entity543 compared with @entity1 with @entity1694 alone; the @entity1709 @entity1 achieve repigmentation much earlier and also attain a greater level of repigmentation. Unexpectedly, for @entity75 , @entity1 with @entity1694 alone responded better than those with both conditions. Although the @entity1709 group with @entity75 started repigmenting earlier, the final pigmentation was more extensive in the @entity1694 group.
